Selective agonists and antagonists for kainate receptors. 2002

Paola Conti, and Marco De Amici, and Carlo De Micheli
Istituto di Chimica Farmaceutica e Tossicologica, Viale Abruzzi 42, Milano, 20131, Italy. paola.conti@unimi.it

Kainate receptors have only recently been characterized both from the pharmacological and biological point of view. Due to the limited number of truly kainate selective ligands, most of the known agonists and antagonists are generally classified as AMPA/kainate receptors ligands. The increasing interest in the search for selective kainate ligands aims at understanding the physiological role played by these receptors and finding out potential therapeutic approaches for the treatment of a number of neurological pathologies, i.e. schizophrenia, as well as acute and chronic neurodegenerative diseases, i.e. epilepsy, cerebral ischaemia, Parkinson's and Alzheimer's diseases. This review will focus on the recently discovered ligands for kainate receptors, with a particular attention given to those molecules displaying a selectivity for the different subunits of the kainate receptors and, on the other hand, to the role played by these receptor subtypes in the pathophysiology of the central nervous system.

UI MeSH Term Description Entries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D018092 Receptors, Kainic Acid A class of ionotropic glutamate receptors characterized by their affinity for KAINIC ACID. Kainate Receptors,Kainic Acid Receptors,Receptors, Kainate,Kainate Receptor,Kainic Acid Receptor,Receptor, Kainate,Receptor, Kainic Acid
D018690 Excitatory Amino Acid Agonists Drugs that bind to and activate excitatory amino acid receptors. Amino Acids, Excitatory, Agonists,Glutamate Agonists,Agonists, Excitatory Amino Acid,Amino Acid Agonist, Excitatory,Amino Acid Agonists, Excitatory,EAA Agonist,EAA Agonists,Excitatory Amino Acid Agonist,Glutamate Agonist,Agonist, EAA,Agonist, Glutamate,Agonists, EAA,Agonists, Glutamate
D018691 Excitatory Amino Acid Antagonists Drugs that bind to but do not activate excitatory amino acid receptors, thereby blocking the actions of agonists. Amino Acids, Excitatory, Antagonists,Excitatory Amino Acid Antagonist,Glutamate Antagonist,Glutamate Antagonists,Glutamate Receptor Antagonist,Amino Acid Antagonists, Excitatory,Antagonists, Excitatory Amino Acid,EAA Antagonists,Glutamate Receptor Antagonists,Antagonist, Glutamate,Antagonist, Glutamate Receptor,Antagonists, EAA,Antagonists, Glutamate,Antagonists, Glutamate Receptor,Receptor Antagonist, Glutamate,Receptor Antagonists, Glutamate
D018696 Neuroprotective Agents Drugs intended to prevent damage to the brain or spinal cord from ischemia, stroke, convulsions, or trauma. Some must be administered before the event, but others may be effective for some time after. They act by a variety of mechanisms, but often directly or indirectly minimize the damage produced by endogenous excitatory amino acids. Neuroprotectant,Neuroprotective Agent,Neuroprotective Drug,Neuroprotectants,Neuroprotective Drugs,Neuroprotective Effect,Neuroprotective Effects,Agent, Neuroprotective,Agents, Neuroprotective,Drug, Neuroprotective,Drugs, Neuroprotective,Effect, Neuroprotective,Effects, Neuroprotective

Related Publications

Paola Conti, and Marco De Amici, and Carlo De Micheli
January 1987, Progress in clinical and biological research,
Paola Conti, and Marco De Amici, and Carlo De Micheli
January 2002, Current pharmaceutical design,
Paola Conti, and Marco De Amici, and Carlo De Micheli
March 2009, Purinergic signalling,
Paola Conti, and Marco De Amici, and Carlo De Micheli
January 2006, Novartis Foundation symposium,
Paola Conti, and Marco De Amici, and Carlo De Micheli
January 2020, Methods in molecular biology (Clifton, N.J.),
Paola Conti, and Marco De Amici, and Carlo De Micheli
March 2022, ACS chemical neuroscience,
Paola Conti, and Marco De Amici, and Carlo De Micheli
January 2001, Farmaco (Societa chimica italiana : 1989),
Paola Conti, and Marco De Amici, and Carlo De Micheli
August 2013, The Journal of pharmacology and experimental therapeutics,
Paola Conti, and Marco De Amici, and Carlo De Micheli
May 1996, Trends in neurosciences,
Copied contents to your clipboard!